[go: up one dir, main page]

CO2018000391A2 - Composiciones farmacéuticas sólidas para el tratamiento del vhc - Google Patents

Composiciones farmacéuticas sólidas para el tratamiento del vhc

Info

Publication number
CO2018000391A2
CO2018000391A2 CONC2018/0000391A CO2018000391A CO2018000391A2 CO 2018000391 A2 CO2018000391 A2 CO 2018000391A2 CO 2018000391 A CO2018000391 A CO 2018000391A CO 2018000391 A2 CO2018000391 A2 CO 2018000391A2
Authority
CO
Colombia
Prior art keywords
solid pharmaceutical
pharmaceutical compositions
compound
pharmaceutically acceptable
hcv
Prior art date
Application number
CONC2018/0000391A
Other languages
English (en)
Inventor
Nancy Sever
Ulrich Westedt
Ute Lander
Katrin Schneider
Benedikt Steitz
Thomas Mueller
Regina Reul
Constanze Obermiller
Adivaraha Jayasankar
Yi Gao
Harald Hach
Samuel Kyeremateng
Ping Tong
Donghua Zhu
Marius Naris
Colleen Garrett
Katharin Asmus
Michael Siimon
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/192,211 external-priority patent/US20160375087A1/en
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CO2018000391A2 publication Critical patent/CO2018000391A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención presenta composiciones farmacéuticas sólidas que comprenden el Compuesto 1 y el Compuesto 2. En una realización, la composición farmacéutica sólida incluye (1) una primera capa que comprende 100 mg de Compuesto 1, así como un polímero hidrófilo farmacéuticamente aceptable y un tensioactivo farmacéuticamente aceptable, todos los cuales están formulados en dispersión sólida amorfa; y (2) una segunda capa que comprende 40 mg de Compuesto 2, así como un polímero hidrófilo farmacéuticamente aceptable y un tensioactivo farmacéuticamente aceptable, todos los cuales están formulados en una dispersión sólida amorfa.
CONC2018/0000391A 2015-07-17 2018-01-16 Composiciones farmacéuticas sólidas para el tratamiento del vhc CO2018000391A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562193639P 2015-07-17 2015-07-17
US201662295309P 2016-02-15 2016-02-15
US15/192,211 US20160375087A1 (en) 2015-06-26 2016-06-24 Solid Pharmaceutical Compositions for Treating HCV
PCT/US2016/042806 WO2017015211A1 (en) 2015-07-17 2016-07-18 Solid pharmaceutical compositions for treating hcv

Publications (1)

Publication Number Publication Date
CO2018000391A2 true CO2018000391A2 (es) 2018-06-12

Family

ID=57834557

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0000391A CO2018000391A2 (es) 2015-07-17 2018-01-16 Composiciones farmacéuticas sólidas para el tratamiento del vhc

Country Status (22)

Country Link
EP (1) EP3324941A1 (es)
JP (2) JP7133466B2 (es)
KR (2) KR102824158B1 (es)
CN (1) CN108024964B (es)
AU (1) AU2016296709C1 (es)
BR (1) BR112018000982A2 (es)
CA (1) CA2992722C (es)
CL (1) CL2018000138A1 (es)
CO (1) CO2018000391A2 (es)
CR (1) CR20180088A (es)
DO (1) DOP2018000024A (es)
EA (1) EA201890334A1 (es)
EC (1) ECSP18008411A (es)
HK (1) HK1255203A1 (es)
IL (1) IL256945B2 (es)
MX (1) MX2018000746A (es)
PE (1) PE20180609A1 (es)
PH (1) PH12018500132A1 (es)
RU (1) RU2018105849A (es)
SG (1) SG10202002900YA (es)
WO (1) WO2017015211A1 (es)
ZA (1) ZA201801082B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN113645958A (zh) * 2019-04-08 2021-11-12 艾伯维公司 用于治疗hcv的固体药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
ES2300188B1 (es) * 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US8716454B2 (en) * 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
PT2498758T (pt) * 2009-11-13 2018-10-23 Astrazeneca Uk Ltd Formulações de comprimido bicamada
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EA029145B1 (ru) * 2010-09-21 2018-02-28 Энанта Фармасьютикалз, Инк. Ингибиторы hcv сериновой протеазы, полученные из макроциклического пролина
SG10201702248UA (en) * 2012-09-18 2017-04-27 Abbvie Inc Methods for treating hepatitis c
PT3213750T (pt) * 2013-03-14 2020-10-19 Abbvie Inc Combinação de dois antivirais para o tratamento da hepatite c
RU2018102809A (ru) * 2015-06-26 2019-07-29 Эббви Инк. Твердые фармацевтические композиции для лечения вируса гепатита с

Also Published As

Publication number Publication date
PE20180609A1 (es) 2018-04-09
CN108024964B (zh) 2022-05-03
JP7133466B2 (ja) 2022-09-08
NZ739127A (en) 2024-05-31
CL2018000138A1 (es) 2018-07-13
PH12018500132A1 (en) 2018-07-23
AU2016296709B2 (en) 2021-11-11
RU2018105849A3 (es) 2019-12-13
BR112018000982A2 (pt) 2018-09-11
AU2016296709A1 (en) 2018-02-08
WO2017015211A1 (en) 2017-01-26
CA2992722C (en) 2023-10-17
EP3324941A1 (en) 2018-05-30
AU2016296709C1 (en) 2022-02-24
ECSP18008411A (es) 2018-04-30
EA201890334A1 (ru) 2018-06-29
IL256945A (en) 2018-03-29
NZ775565A (en) 2024-05-31
CR20180088A (es) 2018-05-24
IL256945B1 (en) 2023-06-01
HK1255203A1 (zh) 2019-08-09
CA2992722A1 (en) 2017-01-26
DOP2018000024A (es) 2018-04-15
JP2018520185A (ja) 2018-07-26
RU2018105849A (ru) 2019-08-19
CN108024964A (zh) 2018-05-11
KR20240108528A (ko) 2024-07-09
ZA201801082B (en) 2018-12-19
KR20180025317A (ko) 2018-03-08
SG10202002900YA (en) 2020-05-28
JP7472199B2 (ja) 2024-04-22
MX2018000746A (es) 2018-08-15
JP2022141719A (ja) 2022-09-29
IL256945B2 (en) 2023-10-01
KR102824158B1 (ko) 2025-06-25

Similar Documents

Publication Publication Date Title
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX385876B (es) Composicion farmaceutica que comprende lenalidomida amorfa y un antioxidante.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2019001993A1 (es) Inhibidores selectivos de jak1.
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CO6400183A2 (es) Formas de dosificación oral de bendamustina
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
CL2021001244A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismos
CO2017007076A2 (es) Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo
ECSP18000689A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
MX390384B (es) Formulaciones farmaceuticas para liberacion sostenida de ester de sebacoil dinalbufina.
ECSP18008411A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
MX2017008373A (es) Compuestos, composiciones y metodos.
MX2020004545A (es) Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa.
MX2019001425A (es) Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.